Skip to main content

Table 3 Toxicity according to National Cancer Institute common toxicity criteria version 3

From: Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

Adverse event

All grades

 

Grade 3/4

 

(safety population n = 78)

 

pts (n)

%

pts (n)

%

Leucopenia

2

2

0

0

Anemia

4

5

1

1

Thrombocytopenia

4

5

1

1

Infection

29

37

6

7

Fatigue/Asthenia

20

25

1

1

Diarrhea

26

33

5

6

Mucositis

14

18

1

1

Nausea

22

28

4

5

Vomiting

9

12

1

1

Anorexia

8

10

1

1

Hand-foot-syndrome

44

57

16

21

Gastrointestinal perforation

2

2

2

2

Hemorrhage

10

13

1

1

Hypertension

17

22

3

4

Thromboembolic events

12

15

8

10

  1. Abbreviation: pts (n) number of patients.